How to carry out internal investigations – a guide for the pharmaceutical sector

14 December 2017
medical_legal_law_big

In an Expert View piece, Rosanne Kay, partner at international law firm Reed Smith, considers when to escalate matters to an internal investigation, and how best to carry them out.

It is relatively unavoidable for many healthcare companies that they will devote resources and time to carrying out internal investigations, whether into allegations that have arisen through whistleblowers or their own monitoring. What are some of the best ways to ensure that such investigations are as effective as possible?

Before beginning

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical